Chemistry and chemical biology of taxane anticancer agents.
about
miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancersLC-ESI-MS analysis of taxoids from the bark of Taxus wallichiana.Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells.Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometryClinical trials and progress with paclitaxel in ovarian cancerLong-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subcloneP18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxaneUse of fluorine in the medicinal chemistry and chemical biology of bioactive compounds--a case study on fluorinated taxane anticancer agents.Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.A study of Docetaxel-induced effects in MCF-7 cells by means of Raman microspectroscopy.Lipid-coated gold nanocomposites for enhanced cancer therapyDocetaxel in the management of ovarian cancer.Sensitivity and mechanisms of taxol-resistant prostate adenocarcinoma cells to Vernonia amygdalina extractBreast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.Ixabepilone for the treatment of taxane-refractory breast cancer.Intrinsic resistance to chemotherapy in breast cancer.Functional p53 determines docetaxel sensitivity in prostate cancer cells.Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells.miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment.mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer.Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.Novel quinazoline HMJ-30 induces U-2 OS human osteogenic sarcoma cell apoptosis through induction of oxidative stress and up-regulation of ATM/p53 signaling pathway.Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.Modeling resistance index of taxoids to MCF-7 cell lines using ANN together with electrotopological state descriptors.Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis.Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarrayApoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes.
P2860
Q28728333-27027189-32F6-4F66-9046-22AAA8B205C6Q31107846-5A8B7B2A-1308-4885-ACB6-E98E91455A96Q33728576-13AA6A99-1F7B-4CD0-B7C1-1D289852AE5CQ33958472-D70BFAA3-EF12-4100-A8F4-644FD993AFADQ34510070-8B879838-C316-46EE-9601-18A74B682A63Q35029319-FCFD4C1B-F804-4C5E-BFEE-8BCE4044BAC2Q35047122-8AEC27FB-7310-461B-BA14-B863B9640306Q35376227-D12400C2-11D7-45D9-84D7-77D052151D63Q35762544-7DD0CB3C-603E-432E-A818-F0E032CC91EDQ35780679-EF5BC72A-AB5E-4064-AB0E-17C3D6E268E9Q35911613-FBEC0355-3F65-44ED-AFFF-20FD9AAF4115Q36010380-BBF369F0-54E2-4CBD-9DE6-734765D890D8Q36118370-FEA7012C-8176-43F5-8675-26DCE3508A91Q36840555-424D96FC-3AC5-4A89-8C78-03CEBD440FDAQ37155629-3D4260D2-2BB0-4C44-AA81-9014AE8FE9B2Q37179381-6D6FCC9F-5DA2-4949-9C18-3E60511C9E3FQ37813694-32B9FA16-B06C-47C3-825B-D06420D423D2Q39274565-673B05BF-9790-451F-AFEE-E0DBFB0872DFQ39303893-E99E6010-05F7-4A5B-B1A3-E257758083D0Q39413683-1F30D32D-F686-432F-8DCD-27C97BD42413Q39420117-628CBD09-422B-45C7-B3FE-AAD9C53882BBQ39506347-74C29A29-501D-4D19-BA32-3086D554A765Q39572504-0B958892-1C8B-4F3E-82F5-48BE97C867B2Q39940476-27760F23-FB5E-4824-BD7C-4804D672B678Q40009078-0F2967D6-88BC-451D-A9CF-ECEAB4410D22Q40284731-A737A031-390A-4A3C-A1FF-989C64DDBE06Q41292697-F3CC6B77-C98C-4C40-BAA5-43CDF5E1D3B5Q41557933-D5EDF7F6-C448-40D6-9D69-5642964417F9Q42751429-51D45363-5F90-41F1-867D-42E1D6B2129AQ43745676-93C9EB1B-92CC-4DC5-BA9A-AB5CA9DCA98FQ46033872-F9025D7A-1C48-4802-A4B9-447BF370F410Q48176143-EBF69316-C6A5-4FCB-A6A2-0F0B0BBA2935
P2860
Chemistry and chemical biology of taxane anticancer agents.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Chemistry and chemical biology of taxane anticancer agents.
@ast
Chemistry and chemical biology of taxane anticancer agents.
@en
Chemistry and chemical biology of taxane anticancer agents.
@nl
type
label
Chemistry and chemical biology of taxane anticancer agents.
@ast
Chemistry and chemical biology of taxane anticancer agents.
@en
Chemistry and chemical biology of taxane anticancer agents.
@nl
prefLabel
Chemistry and chemical biology of taxane anticancer agents.
@ast
Chemistry and chemical biology of taxane anticancer agents.
@en
Chemistry and chemical biology of taxane anticancer agents.
@nl
P2860
P356
P1433
P1476
Chemistry and chemical biology of taxane anticancer agents
@en
P2093
M L Miller
P2860
P304
P356
10.1002/TCR.1008
P50
P577
2001-01-01T00:00:00Z